February 16, 2017
Dauntless Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Octreotide Formulation for Intranasal Delivery
July 21, 2015
Dauntless Pharmaceuticals Launches New Company Focused on Developing a Portfolio of Improved Therapeutics
July 21, 2015New-Era Drug Rx: C-Corp Per Compound And Large Dose of Outsourcing
Dauntless Pharmaceuticals and Aegis Therapeutics Announce Licensing Agreement
September 14, 2015
Dauntless Pharmaceuticals derives its difference with its C-Corp per compound drug-development model.
Fear Not: Sofinnova Backs ‘Dauntless’ Approach to Drug Development
BioWorld Today, July 22, 2015
Dauntless Pharmaceuticals had a smooth initial take-off, fueled by a $12 million series A supporting a single asset, and that’s just the way the San Diego-based company and backer Sofinnova Ventures plan to keep rolling off the runway.
BioPharma M&A: Capital Efficiency Drives Returns
Life Sci VC, May 15, 2015
Optimal and efficient biotech company capital funding is critical to value creation and maximizing returns.
VCs: Adding or Subtracting Value to Biotech Startups?
Life Sci VC, October 14, 2013
Beyond capital investment: key value-added contributions of a good venture capitalist group can greatly aid in the company’s value creation and success. Dauntless Pharmaceuticals has a strong venture capitalist group in Sofinnova Ventures.
New Biotech Corporate Structures: Possible Alternatives For Discovery Platforms and Product Financings
Life Sci VC, September 18, 2012
The advantages of an asset-centric model in biotech. The structure of Dauntless Pharmaceuticals is similar to the model described in this article.
Natural Biotechnology, March 2, 2010
Preferred stock preferences bite into an entrepreneur’s returns. What can you do to put venture capitalists on a diet? The article is authored by Dauntless Pharmaceuticals’ CEO, Dr. Joel Martin.